大族激光(002008.SZ):擬將董事會成員人數由7人增至11人
格隆匯 4 月 7日丨大族激光(002008.SZ)公佈,公司2021年4月7日召開第六屆董事會第四十五次會議,與會董事以同意7票,反對0票,棄權0票,一致通過了《關於增加董事會成員人數並修訂公司章程的議案》,具體內容如下:
根據《大族激光科技產業集團股份有限公司章程》的規定,目前公司董事會成員人數為7人。為進一步提高公司董事會的科學決策能力和水平,優化公司治理,公司擬將董事會成員人數由7人增至11人。
同時,截至2020年12月31日,因公司可轉換公司債券轉股新增股本2676股,轉股完成後,公司總股本變更為1,067,071,941股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.